|Articles|February 15, 2021

Why Are Nursing Homes so Afflicted by COVID-19?

A new study suggests nursing homes with more people of color are actually at three-fold greater risk of COVID-19 mortality.

Perhaps no population has been more adversely affected by the deadly risks of coronavirus 2019 (COVID-19) than US nursing home and long-term care facility residents.

Per the US Centers for Disease Control and Prevention (CDC), 40% of all COVID-19 deaths have been associated with the elder, in-need residents of long-term care facilities. By the CDC’s most recent count, more than 264,000 COVID-19 related deaths in the US have involved persons aged 75 years and older. Add the population aged 65 years and older, and they account for 81% of all deaths in the US from COVID-19.

What’s more, it’s currently clear the virus has disproportionately burdened people of color in the US. CDC data suggest the percentage difference between the rate of COVID-19 deaths and their total representation of the US population is about 20% for Hispanics, and 10% for non-Hispanic Blacks. For Whites, it’s nearly negative 30%.

These are the discriminately burdened communities of COVID-19, and there’s plenty reason to believe the risks blend among key populations.

A new study from the University of Chicago shows nursing homes with the highest proportions of non-White residents experienced COVID-19 death counts that were more 3 times greater than those of facilities with the highest proportions of White residents.

The findings, from Rebecca Gorges, PhD, of the University of Chicago, and colleagues, showed factors including larger nursing home size and higher infection burden in counties were key differences in which nursing homes with high proportions of non-White residents were located.

As the world continue through a phase of the pandemic where more transmissible virus variants have become prevalent, Gorges and colleagues are calling on the use of available, yet limited, available resources for facilities with high proportions of non-White residents to support nursing homes during potential future outbreaks.


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.